Head and neck cancer is the 6th most common cancer worldwide with the most common
histology being squamous cell carcinoma (HNSCC). While the majority of patients present at …

Immunotherapy has revolutionized cancer treatment in the past 2 decades, mostly with
immune checkpoint blockade approaches. In squamous cell carcinoma of the head and …

Preclinical data suggest that head and neck cancer is an intrinsically immunosuppressive
disease with abnormal inflammatory components in the tumor microenvironment. The …

Head and neck squamous cell carcinomas (HNSCCs) are the seventh most common
malignancy worldwide. HNSCCs are highly heterogeneous diseases with varied genetic …

Squamous cell cancer of the head and neck (HNSCC) is the sixth most common cancer and
is associated with significant morbidity and mortality. The tumor microenvironment for …

The immune checkpoint inhibitors, a class of drugs able to block immune suppressive
pathways in order to prime an anticancer immunity, revolutionized standard of care in …

Introduction and background Second-line treatment of platinum-resistant
relapsed/metastatic (R/M) head and neck cancer (HNC) is a currently unmet clinical need …

Head and neck squamous cell cancer (HNSCC) is a malignancy with a rapidly changing
demographic profile, given the recent epidemic of human papilloma virus related cancers …

Head and neck squamous cell carcinoma (HNSCC) is a frequent tumour arising from
multiple anatomical subsites in the head and neck region. The treatment for early-stage …

Objective: Provide a narrative review of the literature describing immunological concepts
and novel approaches in the treatment of head and neck squamous cell carcinoma …